At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 22 enrolled

Drug / intervention

INO-3112 +1 morebiological

Likely dose

INO-3112 1.1 mLfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02163057

NCT02163057Phase 2Completed

Compare CT.gov

Prospective Study of HPV Specific Immunotherapy in Subjects With HPV Associated Head and Neck Squamous Cell Carcinoma (HNSCCa)

Inovio Pharmaceuticals·interventional·Posted Jun 13, 2014·Updated Jan 22, 2021

In Brief

A Phase 2 clinical trial evaluating INO-3112 and CELLECTRA™-5P for Head and Neck Squamous Cell Cancer. Completed, enrolled 22 participants across 1 site.

Detailed Summary

This is a Phase I/IIa, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccine delivered by electroporation (EP) to participants with human papilloma virus (HPV) associated head and neck squamous cell cancer (HNSCC).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHead and Neck Squamous Cell Cancer

CountriesUnited States

CollaboratorsUniversity of Pennsylvania

Timeline

Phase 2CompletedFinished

201520162017201820192020202120222023202420252026

First PostedJun 2014

Enrollment StartAug 2014

Primary CompletionJan 2017

TodayJul 2026

First PostedJun 13, 2014

Enrollment StartAug 13, 2014

Primary CompletionJan 23, 2017

TodayJul 2, 2026

Enrollment to primary: 2.4 yearsPosted 12.1 years ago

Interventions

INO-3112biological

1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered intramuscularly (IM) followed immediately by electroporation (EP) with CELLECTRA™-5P device for a total of 4 doses of immunotherapy.

CELLECTRA™-5Pdevice

CELLECTRA™-5P device was used for EP following IM delivery of INO-3112 for a total of 4 doses of immunotherapy.